Bicara Therapeutics Future Growth
Future criteria checks 0/6
Bicara Therapeutics is forecast to grow earnings and revenue by 12.2% and 63.8% per annum respectively. EPS is expected to grow by 18.8% per annum. Return on equity is forecast to be -156.9% in 3 years.
Key information
12.2%
Earnings growth rate
18.78%
EPS growth rate
| Biotechs earnings growth | 22.8% |
| Revenue growth rate | 63.8% |
| Future return on equity | -156.93% |
| Analyst coverage | Good |
| Last updated | 31 Mar 2026 |
Recent future growth updates
Recent updates
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Mar 31We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate
Jul 15
Bicara: Innovative Precision Tumor Targeting
Apr 19We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth
Mar 13Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me
Feb 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 42 | -216 | -165 | -194 | 9 |
| 12/31/2027 | N/A | -208 | -178 | -188 | 11 |
| 12/31/2026 | N/A | -171 | -154 | -164 | 12 |
| 12/31/2025 | N/A | -138 | -107 | -107 | N/A |
| 9/30/2025 | N/A | -122 | -113 | -113 | N/A |
| 6/30/2025 | N/A | -103 | -101 | -101 | N/A |
| 3/31/2025 | N/A | -92 | -88 | -88 | N/A |
| 12/31/2024 | N/A | -68 | -75 | -75 | N/A |
| 9/30/2024 | N/A | -59 | -53 | -53 | N/A |
| 6/30/2024 | N/A | -65 | -47 | -46 | N/A |
| 3/31/2024 | N/A | -56 | -47 | -47 | N/A |
| 12/31/2023 | N/A | -52 | -46 | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCAX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCAX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCAX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCAX is forecast to have no revenue next year.
High Growth Revenue: BCAX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BCAX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 23:31 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicara Therapeutics Inc. is covered by 14 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Suranjit Mukherjee | BTIG |
| Eric Schmidt | Cantor Fitzgerald & Co. |